RiboFriend (101042574)

  https://cordis.europa.eu/project/id/101042574

  Horizon Europe (2021-2027)

  Deciphering co-translational protein folding, assembly and quality control pathways, in health and disease

  ERC STARTING GRANTS (ERC-2021-STG)

  protein folding  ·  enzymes

  2022-04-01 Start Date (YY-MM-DD)

  2027-03-31 End Date (YY-MM-DD)

  € 1,412,500

  Description

The majority of cellular proteins do not function alone; rather acting together to achieve concerted functions. Despite the prevalence of protein complexes, little is known of the mechanisms that ensure their correct folding and assembly in the crowded cytoplasm. The importance of the folding challenge is underscored by the growing number of misfolding diseases, often characterized by aggregation of lonely, unassembled protein-subunits. At the critical intersection of synthesis and folding, the ribosome is emerging as a hub, guiding the polypeptide-chain interactions with targeting factors, modifying enzymes and folding chaperones. We have recently discovered that even the final step of folding, the assembly into complexes, is coordinated with translation. To capture co-translational events, in vivo, we developed a ribosome profiling approach. This approach revealed that emerging polypeptide-chains are constantly engaged by their partner subunits, protecting them from misfolding (Shiber et al., Nature 2018). However the mechanisms regulating co-translational assembly pathways remain largely obscure. In this proposal, we aim to elucidate co-translational protein folding and degradation mechanisms, in health and disease. We will: (i) Identify and characterize novel co-translational degradation pathways, by targeting ribosomes synthesizing misfolding-prone subunits. (ii) Elucidate the conformational, energetic and kinetic parameters directing folding and assembly, at the atomic level, by molecular dynamics (iii) Develop RiboFriend a single-molecule in vivo approach to elucidate the interplay of chaperones, degradation and assembly factors, during synthesis. Our collective preliminary results strongly support the feasibility of this proposal. The ability to capture co-translational folding and misfolding pathways, in single-molecule resolution can revolutionize our understanding of conformational diseases and the aging process, opening new horizons for therapy.

  Complicit Organisations

1 Israeli organisation participates in RiboFriend.